- Home
- TC vs SLRX Comparison
TC vs SLRX Comparison
Compare TC & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- SLRX
- Stock Information
- Founded
- TC 2010
- SLRX N/A
- Country
- TC China
- SLRX United States
- Employees
- TC N/A
- SLRX N/A
- Industry
- TC Business Services
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- SLRX Health Care
- Exchange
- TC Nasdaq
- SLRX Nasdaq
- Market Cap
- TC 1.9M
- SLRX 2.1M
- IPO Year
- TC 2018
- SLRX N/A
- Fundamental
- Price
- TC $1.00
- SLRX $2.69
- Analyst Decision
- TC
- SLRX
- Analyst Count
- TC 0
- SLRX 0
- Target Price
- TC N/A
- SLRX N/A
- AVG Volume (30 Days)
- TC 178.2K
- SLRX 6.4M
- Earning Date
- TC 08-30-2024
- SLRX 11-14-2024
- Dividend Yield
- TC N/A
- SLRX N/A
- EPS Growth
- TC N/A
- SLRX N/A
- EPS
- TC N/A
- SLRX N/A
- Revenue
- TC $14,107,804.00
- SLRX N/A
- Revenue This Year
- TC N/A
- SLRX N/A
- Revenue Next Year
- TC N/A
- SLRX N/A
- P/E Ratio
- TC N/A
- SLRX N/A
- Revenue Growth
- TC N/A
- SLRX N/A
- 52 Week Low
- TC $0.75
- SLRX $1.22
- 52 Week High
- TC $4.30
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- TC 49.11
- SLRX 61.15
- Support Level
- TC $0.88
- SLRX $2.26
- Resistance Level
- TC $1.03
- SLRX $3.53
- Average True Range (ATR)
- TC 0.10
- SLRX 0.58
- MACD
- TC -0.01
- SLRX 0.11
- Stochastic Oscillator
- TC 32.43
- SLRX 20.60
About TC TuanChe Limited
TuanChe Ltd is an omnichannel automotive marketplace in China. The company operates in one operating segment of providing auto shows, special promotion events services, and virtual dealership, online marketing services, and others. It organizes auto shows, which aim at facilitating transactions between consumers and auto dealers that include auto dealers, automakers, and automotive service providers. It provides services through its online platform and offline events.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.